Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
up to 75 years (Child, Adult) , either sex；
Bone marrow cell morphology examination showed the proportion of primitive and immature lymphocytes in the bone marrow is >5%, or the bone marrow MRD analysis comfirmed as B-ALL.
Flow cytometry or histology confirmed positive expression of cluster of differentiation 19 (CD19);
According to the researcher's assessment, the expected survival period is greater than 3 months;
Pregnant or lactating women, as well as women with pregnancy plans within six months;
Virological tests of hepatitis B, hepatitis C, AIDS, syphilis and cytomegalovirus were positive;
Having a history of other tumors (excluding skin or cervical carcinoma in situ cured by root therapy and without evidence of disease activity);
Previously received treatment targeting CD19;